Lifeward Ltd. LFWD
2.95 USD -0.25 (-7.81%)
Regular-session close
2.50 -0.45 -15.25%
After hours · Nov 19, 4:00 PM ET
2.84 Day range 3.26
2.84 52-week range 9.61
- YTD
- -57.37%
- 1 year
- -55.24%
News
benzinga.com HC Wainwright & Co. Maintains Buy on Lifeward, Lowers Price Target to $8 HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Lifeward (NASDAQ:LFWD) with a Buy and lowers the price target from $10 to $8.
defenseworld.net Head to Head Survey: Lifeward (NASDAQ:LFWD) vs. GN Store Nord (OTCMKTS:GNNDY) Lifeward (NASDAQ: LFWD - Get Free Report) and GN Store Nord (OTCMKTS:GNNDY - Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two businesses…
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers Cerenome (NASDAQ:CNSY) shares rose 39.5% to $1.07 during Friday's regular session. The market value of their outstanding shares is at $5.8 million. As per the press release, Q3 earnings came…
zacks.com Lifeward (LFWD) Reports Q3 Loss, Misses Revenue Estimates Lifeward (LFWD) came out with a quarterly loss of $1.32 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to a loss of $2.4 per share a year ago.benzinga.com Lifeward Q3 Adj. EPS $(1.32) Misses $(0.82) Estimate, Sales $5.428M Miss $7.239M Estimate Lifeward (NASDAQ:LFWD) reported quarterly losses of $(1.32) per share which missed the analyst consensus estimate of $(0.82) by 60.98 percent. This is a 42.11 percent increase over losses of $(2.28)…
globenewswire.com Lifeward Reports Third Quarter 2026 Financial Results and Provides Business Update AlterG revenue increased 18% year-over-year to $3.6 million, driven by higher U.S. unit shipments, service revenue and average selling prices
globenewswire.com Lifeward's ReWalk® Personal Exoskeleton Demonstrates Sustained Long-Term Home Use and Patient Satisfaction in Latest Independent Peer-Reviewed Study Study shows ReWalk can be used for years and provides measurable walking performance for people with chronic paraplegia ReWalk was use d for a median of 33 months, with no reported falls or…
globenewswire.com Peer-Reviewed Study of Lifeward's ReWalk® Exoskeleton Reports Significant Improvements in Daily Activity Performance, Satisfaction, and Pain Landmark independent study reports significantly improved task performance and satisfaction and lower pain compared with wheelchair use
globenewswire.com Lifeward Publishes Updated Investor Presentation Highlighting Commercial Growth Strategy HUDSON, Mass. and YOKNEAM ILLIT, Israel, Sept.
globenewswire.com Lifeward Appoints Josh Hexter Interim Chief Executive Officer and Rami Aviram Chief Financial Officer Experienced leadership team to build on established commercial platform and accelerate Lifeward's next phase of growth with continuity of strategy Experienced leadership team to build on established…
zacks.com Lifeward (LFWD) Reports Q2 Loss, Misses Revenue Estimates Lifeward (LFWD) came out with a quarterly loss of $1.46 per share versus the Zacks Consensus Estimate of a loss of $1.49. This compares to a loss of $6.96 per share a year ago.
globenewswire.com Lifeward Reports Strong Second Quarter 2026 Financial Results as Commercial Execution Drives Growth Revenue increase and operating performance improve as capital-efficient distribution strategy gains momentum Strengthened balance sheet and expanding rehabilitation platform support con tinued…
globenewswire.com Lifeward to Report Second Quarter 2026 Financial Results on August 14, 2026 HUDSON, Mass. and YOKNEAM ILLIT, Israel, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a diversified biomedical innovation company with a portfolio of…
globenewswire.com Lifeward Launches Pilot Program with Ottobock Care to Expand National Access to ReWalk® Personal Exoskeleton Ottobock Care , one of the leading mobility technology patient care organizations in the U.S. , bring s extensive clinical expertise and patient care infrastructure A dvances Lifeward's strategy to…
globenewswire.com Lifeward Secures Growth Capital to Accelerate Commercial Expansion with Up to $11.2 Million in Strategic Financing Initial $5.6 million provides immediate capital to accelerate commercialization of Lifeward's restorative healthcare platform; additional $5.6 million available upon achievement of defined commercial…
gurufocus.com Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation
globenewswire.com Lifeward Appoints Dr. Keith D. Rose as Chief Medical Officer to Support Expansion of Neurorehabilitation Portfolio and Advance Biomed Platform Veteran physician , medical affairs and clinical research leader brings 30 years of rehabilitation medicine experience and deep expertise in neuroscience , mobility technologies , and metabolic…
seekingalpha.com Lifeward Ltd. (LFWD) Q1 2026 Earnings Call Transcript Lifeward Ltd. (LFWD) Q1 2026 Earnings Call Transcript
zacks.com Lifeward (LFWD) Reports Q1 Loss, Lags Revenue Estimates Lifeward (LFWD) came out with a quarterly loss of $6.7 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to a loss of $5.52 per share a year ago.
globenewswire.com Lifeward Reports First Quarter 2026 Financial Results Oramed strategic transaction successfully closed and $10 million financing received Oratech acquisition brings $6. 5 million in cash and promising Protein Oral Delivery ™ biomed technology , with…
globenewswire.com Lifeward to Report First Quarter 2026 Financial Results on May 15, 2026 HUDSON, Mass. and YOKNEAM ILLIT, Israel, May 11, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a diversified biomedical innovation company with a portfolio of…
globenewswire.com Lifeward Announces New ReWalk® Data Presented at ASIA 2026 Conference Demonstrating a Comprehensive Longitudinal Safety Analysis for a Powered Exoskeleton Global data since 2013 show just 3% lifetime fracture prevalence, declining to 0.3% over the past six y ears Zero fractures reported across 97 German users since 2018 , spanning broad patient…
defenseworld.net Lifeward (NASDAQ:LFWD) Trading Up 2.5% – Should You Buy? Lifeward Ltd. (NASDAQ: LFWD - Get Free Report) shares were up 2.5% on Thursday. The stock traded as high as $6.67 and last traded at $6.62. Approximately 4,146 shares changed hands during mid-day…
